Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.

Familial cancer - 1 Jan 2009

Hubert Ayala, Mali Bela, Hamburger Tamar, Rottenberg Yakir, Uziely Beatrice, Peretz Tamar, Kadouri Luna

Abstract excerpt

Pathological features and consequently, tumor response differ between BRCA1/2 carriers and sporadic breast cancer (BC) cases. It is expected that BRCA1/2 associated tumors will be more vulnerable to DNA damaging agents and irradiation due to their function in DNA repair. In addition, very high pa...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Mortality

Share to Neoplasm Invasiveness

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Source

Identifiers

PMID: 19016350
DOI: 10.1007/s10689-008-9223-7

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19016350-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.PMID 19016350Read ↗

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.Semantic proximity Read ↗

Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.Semantic proximity Read ↗

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.Semantic proximity Read ↗

BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.Semantic proximity Read ↗

Systemic therapy options in BRCA mutation-associated breast cancer.Semantic proximity Read ↗

Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcomeSemantic proximity Read ↗

Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases.Semantic proximity Read ↗

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.Semantic proximity Read ↗

Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.Semantic proximity Read ↗

[Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].Semantic proximity Read ↗

Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.Semantic proximity Read ↗

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.